A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

Inclusion Criteria: * Histologically or cytologically confirmed malignant mesothelioma (MM) * Have received only one prior systemic chemotherapy platinum-based regimen for advanced MM * Disease not amenable to curative surgery * No known brain metastasis * Age 18 and over * Performance status 0-2 * Life expectancy \> 12 weeks * Adequate hematologic, hepatic and renal function * Not pregnant or nursing * Patient must be willing and able to provide written informed consent, and the trial have to be approved by the institutional review board at each institution Exclusion Criteria: * Symptomatic chronic inflammatory or autoimmune disease * Active hepatitis B or C * Clinically relevant cardiovascular disease, i.e., myocardial infarction or other severe coronary artery diseases within the prior 6 months, cardiac arrythmia requiring medication, uncontrolled hypertension, overt cardiac failure or not compensated chronic heart disease in NYHA class II or more * History of psychiatric disabilities, potentially interfering with the capability of giving adequate informed consent * Uncontrolled active infections * Other concurrent chemotherapy, immunotherapy, radiotherapy or investigational agents * History of other malignancies except for adequately treated basal cell carcinoma or squamous cell skin cancer or carcinoma of cervix, unless the patient has been disease-free for at least 5 years